U.S. Pharmaceuticals & Biotech Undervalued Solid Performers

Natera

Market Cap: US$29.1b

A diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

United Therapeutics

Market Cap: US$24.1b

Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Roivant Sciences

Market Cap: US$21.5b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.

Neurocrine Biosciences

Market Cap: US$15.8b

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Medpace Holdings

Market Cap: US$12.4b

Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.

BioMarin Pharmaceutical

Market Cap: US$10.5b

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

ICON

Market Cap: US$8.9b

A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

Zai Lab

Market Cap: US$2.1b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.